Pneumonia News and Research

Latest Pneumonia News and Research

PCV-7 vaccine introduction leads to changing patterns of hemolytic uremic syndrome

Introduction of the PCV-7 vaccine to prevent invasive pneumococcal disease (IPD) has led to a shift in the types of bacteria causing hemolytic uremic syndrome (HUS)—an important cause of acute kidney failure in children, reports a study in the August issue of The Pediatric Infectious Disease Journal.

4 Aug 2010

Allergan second-quarter diluted EPS increases to $0.78

Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.

3 Aug 2010

$Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released$

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Millennium: The Takeda Oncology Company today reported new correlative science data from the pivotal PINNACLE trial of VELCADE (bortezomib) in patients with relapsed/refractory mantle cell lymphoma. The data, derived from an analysis of archived tumor samples, tested pre-specified biomarkers for their association with time to progression and response to treatment with VELCADE in patients with relapsed MCL.

30 Jul 2010

GSK exercises option to obtain exclusive licence to develop, commercialise GSK '052

Anacor Pharmaceuticals and GlaxoSmithKline PLC today announced that GSK has exercised its option to obtain an exclusive licence to develop and commercialise GSK2251052 (GSK '052), formerly known as AN3365. GSK '052 is a novel, systemic antibiotic derived from Anacor's boron chemistry platform.

30 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Late preterm births risk infant respiratory illness: Study

Babies born between 34 weeks and 37 weeks gestation are much more likely to have respiratory illness compared to infants born at full term, and their risk of respiratory illness decreases with each additional week of gestation until 38 weeks, researchers report.

28 Jul 2010

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

DIATHERIX Laboratories ,adds a Sexually Transmitted Disease (STD) panel and Herpes Simplex Virus (HSV) panel to its line up of highly sensitive, rapid response diagnostic panels. The HSV panel identifies herpes simplex viruses 1 and 2 and the STD panel identifies 10 sexually transmitted diseases simultaneously, many of which cannot be accurately identified by current testing methods. These STD organisms, if not appropriately treated, can cause diseases such as syphilis, gonorrhoeae, chlamydia, bacterial vaginosis, etc. and may lead to blindness, infertility or complications during pregnancy.

28 Jul 2010

Life-saving interventions can save 11 million African women, children over next five years: Countdown report

In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).

27 Jul 2010

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

26 Jul 2010

AU Summit panel focuses on water, sanitation to meet MDG targets in Africa

African countries should focus on preventing diarrhea - the biggest killer of children in Africa - in order to achieve Millennium Development Goal targets, Yunia Musaazi, WaterAid's East Africa policy advisor, told delegates at the 15th African Union Summit, PANA/Afrique en ligne reports.

26 Jul 2010

Scientists study Legionella's reprogramming on cells for survival, propagation

When it infects the lungs, the Legionnaire's bacterium Legionella pneumophila causes acute pneumonia. The pathogen's modus operandi is particularly ingenious: it infiltrates deliberately into cells of the human immune system and injects a host of proteins which then interfere in the normal cellular processes. Scientists from the Max Planck Institute of Molecular Physiology in Dortmund have now discovered how Legionella reprogrammes the cells to ensure its own survival and to propagate. They examined a protein used by the pathogen to divert the material transport within the cells for its own purposes.

26 Jul 2010

Advanced Life Sciences enters debt for equity exchange agreement with CEO

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has entered into a debt for equity exchange agreement with its chairman and CEO Michael T. Flavin, Ph.D.

23 Jul 2010

New rules Thursday on appealing insurance claims, states take lead in health reform implementation

Kaiser Health News /The Washington Post obtained a summary of new rules to be released Thursday by the Obama administration that will make it easier for consumers to appeal the denials of their health insurance claims as the White House tries to "boost political support" for the new health law.

23 Jul 2010

Pneumonia, diarrhea, and malaria cause death of 6 million of world's poorest children

A Johns Hopkins University scientist, whose team of researchers recently identified pneumonia, diarrhea, and malaria as the primary causes of death of 6 million of the world's poorest children, today called on leaders in donor and developing nations to take action to address the terrible death toll.

23 Jul 2010

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases confirmed that testing of two (2) of the company's compounds Onconase (Ranpirnase), and recombinant Amphinase 2 showed positive in vitro results for Severe Acute Respiratory Syndrome, also known as (SARS) virus.

22 Jul 2010

Medicare Star Support Program launched to help Medicare Advantage plans boost star ratings

Health Dialog today announced that it has launched its Medicare Star Support Program to help Medicare Advantage plans boost their Health Plan Quality and Performance ("Star") Ratings and ensure that seniors are getting the best care possible. Star ratings are calculated by the Centers for Medicare & Medicaid Services and can range from 1 to 5, with 5 representing the highest quality.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

19 Jul 2010

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

A pneumococcal conjugate vaccine introduced in the U.S. 10 years ago appears to reduce pneumonia and serious associated complications, such as blood infections, in the vaccine's target range, children less than a year old, according to new research.

19 Jul 2010

Insight into inner functional mechanisms of new bacterial infection target

In any battle, sizing up one's opponent is a critical first step. For researchers fighting a bacterial infection, that means assessing every nook and cranny of the malicious microorganism and identifying which ones to attack.

14 Jul 2010

Pneumonia News and Research

Latest Pneumonia News and Research

PCV-7 vaccine introduction leads to changing patterns of hemolytic uremic syndrome

Allergan second-quarter diluted EPS increases to $0.78

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

GSK exercises option to obtain exclusive licence to develop, commercialise GSK '052

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Late preterm births risk infant respiratory illness: Study

DIATHERIX Laboratories opens rapid response diagnostic panels for STD, HSV

Life-saving interventions can save 11 million African women, children over next five years: Countdown report

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

AU Summit panel focuses on water, sanitation to meet MDG targets in Africa

Scientists study Legionella's reprogramming on cells for survival, propagation

Advanced Life Sciences enters debt for equity exchange agreement with CEO

New rules Thursday on appealing insurance claims, states take lead in health reform implementation

Pneumonia, diarrhea, and malaria cause death of 6 million of world's poorest children

Onconase, Amphinase 2 show positive results for SARS virus: Tamir Biotechnology

Medicare Star Support Program launched to help Medicare Advantage plans boost star ratings

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

Insight into inner functional mechanisms of new bacterial infection target

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Pneumonia News and Research

Latest Pneumonia News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in